Loading…
AURO-TRANDOLAPRIL is a brand name for Trandolapril, supplied as a capsule. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: AND CLINICAL USE .............................................................................. 3 CONTRAINDICATIONS ................................................................................................... 4 WARNINGS AND PRECAUTIONS…
Verbatim from this product's HC label. Tap a section to expand.
). Should the patient receiving AURO-TRANDOLAPRIL experience any unexplained symptoms, particularly during the first weeks or months of treatment, it is recommended that a full set of liver function tests and any other necessary investigations be carried out.
Discontinuation of AURO-TRANDOLAPRIL should be considered when appropriate (see ACTION AND CLINICAL PHARMACOLOGY, Special Populations and Conditions, Hepatic Insufficiency). Immune Angioedema Angioedema has been reported in patients taking ACE inhibitors, including trandolapril.
Angioedema associated with laryngeal involvement may be fatal. If laryngeal stridor or angioedema of the face, tongue, or glottis occurs, AURO-TRANDOLAPRIL should be discontinued immediately, the patient treated appropriately in accordance with accepted medical care, and carefully observed until the swelling disappears.
In instances where swelling is confined to the face and lips, the condition generally resolves without treatment. 5 mL of subcutaneous epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS). Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor (see CONTRAINDICATIONS).
The incidence of angioedema during ACE inhibition therapy has been reported to be higher in black than in non-black patients. g. sirolimus, everolimus, temsirolimus) or neutral endopeptidase (NEP) inhibitor. Caution should be used when initiating ACE inhibitor therapy in patients already taking a mTOR, or NEP inhibitor or vice versa.
(see DRUG INTERACTIONS Drug- Drug Interactions). Do not initiate AURO-TRANDOLAPRIL until at least 36 hours have elapsed following the last dose of sacubitril/valsartan. In the case of a switch from AURO- TRANDOLAPRIL to sacubitril/valsartan, do not start sacubitril/valsartan until at least 36 hours have elapsed following the last dose of AURO-TRANDOLAPRIL.
(see CONTRAINDICATIONS and DRUG INTERACTIONS Drug-Drug Interactions). Intestinal angioedema has also been reported in patients treated with ACE inhibitors. These patients presented with abdominal pain (with or without nausea or vomiting); in some cases there was no prior history of facial angioedema and C-1 esterase levels were normal.
The angioedema was diagnosed by procedures including abdominal CT scan or ultrasound, or at surgery, and symptoms resolved after stopping the ACE inhibitor. Intestinal angioedema should be included in the differential diagnosis of patients on ACE inhibitors presenting with abdominal pain.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Trandolapril in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Anaphylactoid Reactions during Desensitization There have been isolated reports of patients experiencing sustained life-threatening anaphylactoid reactions while receiving ACE inhibitors during desensitization treatment with hymenoptera Page 9 of 42 (bees, wasps) venom.
In the same patients, these reactions have been avoided when ACE inhibitors were temporarily withheld for ≥24 hours, but they have reappeared upon inadvertent rechallenge. Anaphylactoid Reactions during Low-Density Lipoprotein (LDL)-Apharesis Life-threatening anaphylactoid reactions have been noted when patients on LDL-apharesis with dextran sulfate take ACE inhibitors at the same time.
These reactions were avoided by temporarily withholding ACE inhibitor therapy prior to each apheresis. , polyacrylonitrile [PAN]) and treated concomitantly with an ACE inhibitor. Dialysis should be stopped immediately if symptoms such as nausea, abdominal cramps, burning, angioedema, shortness of breath and severe hypotension occur.
Symptoms are not relieved by antihistamines. In these patients consideration should be given to using a different type of dialysis membrane or a different class of antihypertensive agents. Other Lactose This medicine contains lactose, therefore patients with rare hereditary forms of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption syndrome should not take this medicine (see CONTRAINDICATIONS).
Nitritoid Reactions Gold:
Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and symptomatic hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including trandolapril (see DRUG INTERACTIONS).
Peri-Operative Considerations The hypotensive effects of certain inhalation anesthetics may be enhanced by ACE inhibitors. In patients undergoing surgery or anesthesia with agents producing hypotension, AURO- TRANDOLAPRIL will block angiotensin II formation secondary to compensatory renin release.
If hypotension occurs and is considered to be due to this mechanism, it may be corrected by volume repletion (see DRUG INTERACTIONS, Table 3, Inhalation anesthetics). Renal Renal Impairment As a consequence of inhibiting the renin-angiotensin-aldosterone system (RAAS), changes in renal function have been seen in susceptible individuals.
In patients whose renal function may depend on the activity of the RAAS, such as patients with bilateral renal artery stenosis, unilateral renal artery stenosis to a solitary kidney, or severe congestive heart failure, treatment with agents that inhibit this system has been associated with oliguria, progressive azotemia, and rarely, acute renal failure and/or death.
In susceptible patients, concomitant diuretic use may further increase Page 10 of 42 risk. Proteinuria may occur particularly in patients with existing renal function impairment or on relatively high doses of ACE inhibitors. The use of ACE inhibitors – […]